Latest hepatitis C Stories
Genomics R&D firm, Ryogen LLC, has been awarded two U.S.
Dr. Joseph Boscarino's research into disease that claimed his brother a major breakthrough DANVILLE, Pa., Aug.
Reimbursement and Out-of-Pocket Costs are the Leading Reasons for Treatment Discontinuation, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug.
Newly implemented screening guidelines and improved, highly effective drug therapies could make hepatitis C a rare disease in the United States by 2036.
Newly implemented screening guidelines and improved, highly effective drug therapies could make hepatitis C a rare disease in the United States by 2036, according to the results of a predictive
Doctor Evidence, LLC has developed a comprehensive database of clinical evidence in Hepatitis C (HCV) to address the evolving needs of healthcare stakeholders. Santa
San Antonio researcher leads national study that identified a combination of pills that cures 9 of 10 hepatitis C patients. San Antonio, TX (PRWEB) July 29,
New Treatments Can Significantly Transform the Face of Hep C LA JOLLA, Calif.
Two new pill-only antiviral drug regimens could provide shorter, more effective treatment options with fewer side effects for the majority of patients infected with hepatitis C, even those most difficult to treat.
New study identifies potential alternatives to Gilead's Sovaldi PHILADELPHIA, July 28, 2014 /PRNewswire/ -- The Intellectual
Hepatitis C virus (HCV) is an enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. It consists of a core of genetic material surrounded by an icosahedra protective shell of protein. The genome consists of a single open reading frame that is 9600 nucleotide bases long. HCV replication takes several steps. It primarily replicates in the hepatocytes of the liver. It can also reproduce in peripheral blood mononuclear cells. There is a wide variety of genotypes and...